Novo Nordisk filed a lawsuit against Eli Lilly in federal court in New Jersey, reported July 21, 2026. The complaint centers on promotional activity for GLP-1–based obesity and diabetes therapies and alleges that Lilly ran a nationwide advertising campaign the plaintiff characterizes as deceptive advertising.
The article identifying the filing was published by STAT News reporters Ed Silverman and Elaine Chen. The piece notes this legal action as the latest development in an ongoing, intense commercial rivalry between the two companies competing in the GLP-1 therapeutic space.
According to Novo Nordisk’s complaint as summarized in the reporting, Eli Lilly compared the highest doses of its weight-loss drug Zepbound and diabetes drug Mounjaro with lower doses of Novo Nordisk’s products Wegovy and Ozempic. Novo’s filing contends that some of the data Lilly used in its advertising are from what Novo calls “outdated clinical trials,” and that these comparisons make Lilly’s products appear more effective.
The story describes Novo’s core allegation as a pattern of advertising that, in its view, misleads or confuses consumers by presenting comparisons that do not reflect equivalent dosing or contemporaneous trial contexts. The article does not reproduce the complaint’s legal text or list the specific advertisements at issue.
Novo Nordisk’s general counsel and senior vice president, John Kuckelman, is quoted in the reporting saying, “What has brought us to this moment is what we now see as a nationwide pattern, by Lilly, of deceptive advertising. They are intentionally confusing consumers.” This remark is presented as reflecting Novo Nordisk’s public rationale for seeking judicial intervention.
The article does not include a response from Eli Lilly or any additional comment from either company beyond the quoted statement from Novo’s counsel. It also does not specify the remedies Novo Nordisk is requesting from the court or the particular statutory or regulatory claims advanced in the filing.
STAT frames the lawsuit as an escalation in what it calls one of the pharmaceutical industry’s most intense rivalries. Both firms are major players in the evolving market for GLP-1 receptor agonists used for obesity and diabetes, and competitive messaging around comparative efficacy and dosing has become a focal point in commercial disputes.
The article highlights the strategic stakes of such advertising disputes without providing a detailed history of prior legal or regulatory actions between the companies, specific market-share data, or clinical comparisons beyond the allegations described in the complaint.
The source article provides a concise summary of the lawsuit and Novo Nordisk’s public accusation but omits several details one might expect in a full legal report. The STAT piece does not:
Because those items were not reported in the source, they cannot be confirmed or expanded upon here.
Summary
Novo Nordisk’s July 21, 2026 lawsuit in New Jersey accuses Eli Lilly of a nationwide pattern of deceptive advertising for GLP-1 drugs by comparing Lilly’s highest-dose products (Zepbound, Mounjaro) with lower doses of Novo Nordisk’s Wegovy and Ozempic, and by relying on what Novo describes as outdated clinical trials. Novo’s general counsel characterized the conduct as intentionally confusing to consumers. The STAT report supplies these allegations and context about the rivalry but does not include Lilly’s response or detailed legal and evidentiary specifics from the complaint.